Download PDF
Aktuelle Neurologie 2017; 44(09): 637-644
DOI: 10.1055/s-0043-110140
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Konzepte zur prähospitalen und initialen intrahospitalen Therapie des Status epilepticus

Concepts for Prehospital and Initial In-hospital Therapy of Status Epilepticus
Adam Strzelczyk
1   Goethe-Universität Frankfurt, Epilepsiezentrum Frankfurt Rhein-Main
2   Philipps-Universität Marburg, Epilepsiezentrum Hessen
,
Lara Kay
1   Goethe-Universität Frankfurt, Epilepsiezentrum Frankfurt Rhein-Main
,
Christoph Kellinghaus
3   Klinikum Osnabrück GmbH, Epilepsiezentrum Münster-Osnabrück
,
Susanne Knake
2   Philipps-Universität Marburg, Epilepsiezentrum Hessen
,
Anemone von Blomberg
1   Goethe-Universität Frankfurt, Epilepsiezentrum Frankfurt Rhein-Main
,
Laurent M. Willems
1   Goethe-Universität Frankfurt, Epilepsiezentrum Frankfurt Rhein-Main
,
Felix Rosenow
1   Goethe-Universität Frankfurt, Epilepsiezentrum Frankfurt Rhein-Main
2   Philipps-Universität Marburg, Epilepsiezentrum Hessen
› Author Affiliations
Further Information

Publication History

Publication Date:
13 September 2017 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Der Status epilepticus gehört zu den wichtigsten neurologischen Notfallsituationen, die eine sofortige medizinische Behandlung erfordern. Eine schnelle und ausreichend dosierte Behandlung ist wichtig, um das Therapieoutcome zu optimieren und die Mortalität zu reduzieren. Hier geben wir einen Überblick über Konzepte zur akuten prähospitalen und initialen intrahospitalen Behandlung des Status epilepticus. Die Möglichkeiten der initialen Therapie ohne Überwachungsmöglichkeiten einer Intensivstation werden ausführlich vorgestellt.

Abstract

Status epilepticus is a major neurological emergency requiring immediate medical treatment. Rapid and sufficient treatment is essential for optimizing outcome and reducing mortality. Here, we give an overview on concepts for acute prehospital and initial in-hospital treatment of status epilepticus. Options for initial therapy in settings without intensive care monitoring are presented in detail.

Schlüsselwörter

epileptischer Anfall - intranasal - Benzodiazepine - Antikonvulsiva - bukkal

Key words

seizure - intranasal - benzodiazepines - anticonvulsants - buccal
 

  • Literatur

  • 1 Betjemann JP, Lowenstein DH. Status epilepticus in adults. Lancet Neurol 2015; 14: 615-624
    CrossrefPubMedGoogle Scholar
  • 2 Knake S, Rosenow F, Vescovi M. et al. Incidence of status epilepticus in adults in Germany: a prospective, population-based study. Epilepsia 2001; 42: 714-718
    CrossrefPubMedGoogle Scholar
  • 3 Kortland LM, Alfter A, Bahr O. et al. Costs and cost-driving factors for acute treatment of adults with status epilepticus: A multicenter cohort study from Germany. Epilepsia 2016; 57: 2056-2066
    CrossrefPubMedGoogle Scholar
  • 4 Strzelczyk A, Knake S, Oertel WH. et al. Inpatient treatment costs of status epilepticus in adults in Germany. Seizure 2013; 22: 882-885
    CrossrefPubMedGoogle Scholar
  • 5 Trinka E, Cock H, Hesdorffer D. et al. A definition and classification of status epilepticus – Report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia 2015; 56: 1515-1523
    CrossrefPubMedGoogle Scholar
  • 6 Rosenow F. Status epilepticus im Erwachsenenalter. In: Diener HC, Weimar C. Hrsg. Leitlinien für Diagnostik und Therapie in der Neurologie. Stuttgart: Thieme Verlag; 2012
    Google Scholar
  • 7 Lowenstein DH, Bleck T, Macdonald RL. Itʼs time to revise the definition of status epilepticus. Epilepsia 1999; 40: 120-122
    CrossrefPubMedGoogle Scholar
  • 8 Lowenstein DH, Alldredge BK. Status epilepticus at an urban public hospital in the 1980s. Neurology 1993; 43: 483-488
    CrossrefPubMedGoogle Scholar
  • 9 Kapur J, Macdonald RL. Rapid seizure-induced reduction of benzodiazepine and Zn2+ sensitivity of hippocampal dentate granule cell GABAA receptors. J Neurosci 1997; 17: 7532-7540
    CrossrefPubMedGoogle Scholar
  • 10 Alldredge BK, Gelb AM, Isaacs SM. et al. A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. N Engl J Med 2001; 345: 631-637
    CrossrefPubMedGoogle Scholar
  • 11 Shorvon S, Ferlisi M. The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain 2011; 134: 2802-2818
    CrossrefPubMedGoogle Scholar
  • 12 Holtkamp M, Othman J, Buchheim K. et al. A “malignant” variant of status epilepticus. Arch Neurol 2005; 62: 1428-1431
    CrossrefPubMedGoogle Scholar
  • 13 Strzelczyk A, Kortland LM, Knake S. et al. Stiripentol for the treatment of super-refractory status epilepticus. Acta Neurol Scand 2015; 132: 435-439
    CrossrefPubMedGoogle Scholar
  • 14 Thakur KT, Probasco JC, Hocker SE. et al. Ketogenic diet for adults in super-refractory status epilepticus. Neurology 2014; 82: 665-670
    CrossrefPubMedGoogle Scholar
  • 15 Rohracher A, Hofler J, Kalss G. et al. Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit. Epilepsy Behav 2015; 49: 354-358
    CrossrefPubMedGoogle Scholar
  • 16 Broomall E, Natale JE, Grimason M. et al. Pediatric super-refractory status epilepticus treated with allopregnanolone. Ann Neurol 2014; 76: 911-915
    CrossrefPubMedGoogle Scholar
  • 17 Levesque M, Herrington R, Leclerc L. et al. Allopregnanolone decreases interictal spiking and fast ripples in an animal model of mesial temporal lobe epilepsy. Neuropharmacology 2017; 121: 12-19
    CrossrefPubMedGoogle Scholar
  • 18 Chen JW, Wasterlain CG. Status epilepticus: pathophysiology and management in adults. The Lancet Neurol 2006; 5: 246-256
    CrossrefPubMedGoogle Scholar
  • 19 Prasad M, Krishnan PR, Sequeira R. et al. Anticonvulsant therapy for status epilepticus. The Cochrane database of systematic reviews; 2014 DOI: 10.1002/14651858.CD003723.pub3 CD003723
    CrossrefPubMedGoogle Scholar
  • 20 Crevoisier C, Delisle MC, Joseph I. et al. Comparative single-dose pharmacokinetics of clonazepam following intravenous, intramuscular and oral administration to healthy volunteers. Eur Neurol 2003; 49: 173-177
    CrossrefPubMedGoogle Scholar
  • 21 Alvarez V, Lee JW, Drislane FW. et al. Practice variability and efficacy of clonazepam, lorazepam, and midazolam in status epilepticus: A multicenter comparison. Epilepsia 2015; 56: 1275-1285
    CrossrefPubMedGoogle Scholar
  • 22 Silbergleit R, Lowenstein D, Durkalski V. et al. RAMPART (Rapid Anticonvulsant Medication Prior to Arrival Trial): a double-blind randomized clinical trial of the efficacy of intramuscular midazolam versus intravenous lorazepam in the prehospital treatment of status epilepticus by paramedics. Epilepsia 2011; 52 (Suppl. 08) 45-47
    PubMedGoogle Scholar
  • 23 Silbergleit R, Durkalski V, Lowenstein D. et al. Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med 2012; 366: 591-600
    CrossrefPubMedGoogle Scholar
  • 24 Welch RD, Nicholas K, Durkalski-Mauldin VL. et al. Intramuscular midazolam versus intravenous lorazepam for the prehospital treatment of status epilepticus in the pediatric population. Epilepsia 2015; 56: 254-262
    CrossrefPubMedGoogle Scholar
  • 25 Silbergleit R, Lowenstein D, Durkalski V. et al. Lessons from the RAMPART study – and which is the best route of administration of benzodiazepines in status epilepticus. Epilepsia 2013; 54 (Suppl. 06) 74-77
    CrossrefPubMedGoogle Scholar
  • 26 Crawford TO, Mitchell WG, Snodgrass SR. Lorazepam in childhood status epilepticus and serial seizures: effectiveness and tachyphylaxis. Neurology 1987; 37: 190-195
    CrossrefPubMedGoogle Scholar
  • 27 Scott RC, Besag FM, Neville BG. Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomised trial. Lancet 1999; 353: 623-626
    CrossrefPubMedGoogle Scholar
  • 28 Lahat E, Goldman M, Barr J. et al. Comparison of intranasal midazolam with intravenous diazepam for treating febrile seizures in children: prospective randomised study. BMJ 2000; 321: 83-86
    CrossrefPubMedGoogle Scholar
  • 29 Fisgin T, Gurer Y, Tezic T. et al. Effects of intranasal midazolam and rectal diazepam on acute convulsions in children: prospective randomized study. J Child Neurol 2002; 17: 123-126
    CrossrefPubMedGoogle Scholar
  • 30 Mahmoudian T, Zadeh MM. Comparison of intranasal midazolam with intravenous diazepam for treating acute seizures in children. Epilepsy Behav 2004; 5: 253-255
    CrossrefPubMedGoogle Scholar
  • 31 McIntyre J, Robertson S, Norris E. et al. Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: a randomised controlled trial. Lancet 2005; 366: 205-210
    CrossrefPubMedGoogle Scholar
  • 32 Ashrafi MR, Khosroshahi N, Karimi P. et al. Efficacy and usability of buccal midazolam in controlling acute prolonged convulsive seizures in children. Eur J Paediatr Neurol 2010; 14: 434-438
    CrossrefPubMedGoogle Scholar
  • 33 de Haan GJ, van der Geest P, Doelman G. et al. A comparison of midazolam nasal spray and diazepam rectal solution for the residential treatment of seizure exacerbations. Epilepsia 2010; 51: 478-482
    CrossrefPubMedGoogle Scholar
  • 34 Holsti M, Dudley N, Schunk J. et al. Intranasal midazolam vs rectal diazepam for the home treatment of acute seizures in pediatric patients with epilepsy. Arch Pediatr Adolesc Med 2010; 164: 747-753
    PubMedGoogle Scholar
  • 35 Arya R, Gulati S, Kabra M. et al. Intranasal versus intravenous lorazepam for control of acute seizures in children: a randomized open-label study. Epilepsia 2011; 52: 788-793
    CrossrefPubMedGoogle Scholar
  • 36 McMullan J, Sasson C, Pancioli A. et al. Midazolam versus diazepam for the treatment of status epilepticus in children and young adults: a meta-analysis. Acad Emerg Med 2010; 17: 575-582
    PubMedGoogle Scholar
  • 37 Thakker A, Shanbag P. A randomized controlled trial of intranasal-midazolam versus intravenous-diazepam for acute childhood seizures. J Neurol 2013; 260: 470-474
    CrossrefPubMedGoogle Scholar
  • 38 Kay L, Reif PS, Belke M. et al. Intranasal midazolam during presurgical epilepsy monitoring is well tolerated, delays seizure recurrence, and protects from generalized tonic-clonic seizures. Epilepsia 2015; 56: 1408-1414
    CrossrefPubMedGoogle Scholar
  • 39 Kriel RL, Cloyd JC, Hadsall RS. et al. Home use of rectal diazepam for cluster and prolonged seizures: efficacy, adverse reactions, quality of life, and cost analysis. Ped Neurol 1991; 7: 13-17
    CrossrefPubMedGoogle Scholar
  • 40 Timmerman A, Jennekens-Schinkel A, Oostrom KJ. et al. Stesolid emergency treatment: cave social fear!. Seizure 2008; 17: 333-338
    CrossrefPubMedGoogle Scholar
  • 41 Tatum IW. Adult patient perceptions of emergency rectal medications for refractory seizures. Epilepsy Behav 2002; 3: 535-538
    CrossrefPubMedGoogle Scholar
  • 42 Brigo F, Nardone R, Tezzon F. et al. A common reference-based indirect comparison meta-analysis of buccal versus intranasal midazolam for early status epilepticus. CNS Drugs 2015; 29: 741-757
    CrossrefPubMedGoogle Scholar
  • 43 Trinka E, Brigo F, Shorvon S. Recent advances in status epilepticus. Curr Op Neurology 2016; 29: 189-198
    PubMedGoogle Scholar
  • 44 Treiman DM, Meyers PD, Walton NY. et al. A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med 1998; 339: 792-798
    CrossrefPubMedGoogle Scholar
  • 45 Kuruvilla T, Bharucha NE. Cerebellar atrophy after acute phenytoin intoxication. Epilepsia 1997; 38: 500-502
    CrossrefPubMedGoogle Scholar
  • 46 Rohracher A, Reiter DP, Brigo F. et al. Status epilepticus in the elderly – a retrospective study on 120 patients. Epilepsy Res 2016; 127: 317-323
    CrossrefPubMedGoogle Scholar
  • 47 Sutter R, Marsch S, Fuhr P. et al. Anesthetic drugs in status epilepticus: risk or rescue? A 6-year cohort study. Neurology 2014; 82: 656-664
    CrossrefPubMedGoogle Scholar
  • 48 Kellinghaus C, Stogbauer F. Treatment of status epilepticus in a large community hospital. Epilepsy Behav 2012; 23: 235-240
    CrossrefPubMedGoogle Scholar
  • 49 Ertl J, Hapfelmeier J, Peckmann T. et al. Guideline conform initial monotherapy increases in patients with focal epilepsy: a population-based study on German health insurance data. Seizure 2016; 41: 9-15
    CrossrefPubMedGoogle Scholar
  • 50 Strzelczyk A, Bergmann A, Biermann V. et al. Neurologist adherence to clinical practice guidelines and costs in patients with newly diagnosed and chronic epilepsy in Germany. Epilepsy Behav 2016; 64: 75-82
    CrossrefPubMedGoogle Scholar
  • 51 Bede P, Lawlor D, Solanki D. et al. Carbapenems and valproate: A consumptive relationship. Epilepsia Open 2017; 2: 107-111
    CrossrefPubMedGoogle Scholar
  • 52 Strzelczyk A, Zöllner JP, Willems LM. et al. Lacosamide in status epilepticus: Systematic review of current evidence. Epilepsia 2017; 58: 933-950
    CrossrefPubMedGoogle Scholar
  • 53 Hofler J, Unterberger I, Dobesberger J. et al. Intravenous lacosamide in status epilepticus and seizure clusters. Epilepsia 2011; 52: e148-152
    CrossrefPubMedGoogle Scholar
  • 54 Kellinghaus C, Berning S, Immisch I. et al. Intravenous lacosamide for treatment of status epilepticus. Acta Neurol Scand 2011; 123: 137-141
    CrossrefPubMedGoogle Scholar
  • 55 Lang N, Lange M, Schmitt FC. et al. Intravenous lacosamide in clinical practice – results from an independent registry. Seizure 2016; 39: 5-9
    CrossrefPubMedGoogle Scholar
  • 56 Strzelczyk A, Steinig I, Willems LM. et al. Treatment of refractory and super-refractory status epilepticus with brivaracetam: A cohort study from two German university hospitals. Epilepsy Behav 2017; 70 (Pt A): 177-181
    CrossrefPubMedGoogle Scholar
  • 57 Steinig I, von Podewils F, Moeddel G. et al. Postmarketing experience with brivaracetam in the treatment of epilepsies: a multicentre cohort study from Germany. Epilepsia 2017; DOI: 10.1111/epi.13768.
    CrossrefPubMedGoogle Scholar
  • 58 Yates SL, Fakhoury T, Liang W. et al. An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam. Epilepsy Behav 2015; 52: 165-168
    CrossrefPubMedGoogle Scholar
  • 59 Brandt C, May TW, Bien CG. Brivaracetam as adjunctive therapy for the treatment of partial-onset seizures in patients with epilepsy: the current evidence base. Ther Adv Neurol Dis 2016; 9: 474-482
    CrossrefPubMedGoogle Scholar
  • 60 Strzelczyk A, Klein KM, Willems LM. et al. Brivaracetam in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus. Expert Rev Clinical Pharmacol 2016; 9: 637-645
    PubMedGoogle Scholar
  • 61 Nicolas JM, Hannestad J, Holden D. et al. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action. Epilepsia 2016; 57: 201-209
    CrossrefPubMedGoogle Scholar
  • 62 Jones S, Pahl C, Trinka E. et al. A protocol for the inhospital emergency drug management of convulsive status epilepticus in adults. Pract Neurol 2014; 14: 194-197
    CrossrefPubMedGoogle Scholar
  • 63 ABDA – Bundesvereinigung Deutscher Apothekerverbände. Neues Rezeptur-Formularium. Midazolam-Rezepturen. 2002
    PubMedGoogle Scholar